ArticleVaccines2024

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial.

Veronica V Rezelj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.